Cargando…

CAR-NK Cells Targeting HER1 (EGFR) Show Efficient Anti-Tumor Activity against Head and Neck Squamous Cell Carcinoma (HNSCC)

SIMPLE SUMMARY: Despite new therapeutic approaches in the last decades, prognosis and survival rates for head and neck squamous cell carcinomas (HNSCC) remain poor. Due to its high immune cell infiltration, immunotherapy has become a valuable tool for HNSCC, yet only three monoclonal antibodies have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nowak, Juliette, Bentele, Marco, Kutle, Ivana, Zimmermann, Katharina, Lühmann, Jonathan Lukas, Steinemann, Doris, Kloess, Stephan, Koehl, Ulrike, Roßberg, Willi, Ahmed, Amed, Schaudien, Dirk, Neubert, Lavinia, Kamp, Jan-Christopher, Kuehnel, Mark P., Warnecke, Athanasia, Schambach, Axel, Morgan, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296665/ https://www.ncbi.nlm.nih.gov/pubmed/37370779 http://dx.doi.org/10.3390/cancers15123169

Ejemplares similares

Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123
por: Morgan, Michael A., et al.
Publicado: (2021)

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
por: Chauhan, Sachin Kumar Singh, et al.
Publicado: (2020)

Advantages and applications of CAR-expressing natural killer cells
por: Glienke, Wolfgang, et al.
Publicado: (2015)

Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering
por: Oberschmidt, Olaf, et al.
Publicado: (2019)

Use of Cell and Genome Modification Technologies to Generate Improved “Off-the-Shelf” CAR T and CAR NK Cells
por: Morgan, Michael A., et al.
Publicado: (2020)

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids
por: Giannattasio, Ariane, et al.
Publicado: (2015)

Zungengrundhyperplasie nach Tonsillektomie und Korrelation mit dem BMI
por: Roßberg, Willi, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

Comprehensive three‐dimensional morphology of neoangiogenesis in pulmonary veno‐occlusive disease and pulmonary capillary hemangiomatosis
por: Neubert, Lavinia, et al.
Publicado: (2019)

Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
por: Seliger, Barbara, et al.
Publicado: (2022)

Bioinformatic Analysis of the Perilymph Proteome to Generate a Human Protein Atlas
por: van Dieken, Alina, et al.
Publicado: (2022)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
por: Ciulean, Ioana Sonya, et al.
Publicado: (2023)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

High Risk-Human Papillomavirus in HNSCC: Present and Future Challenges for Epigenetic Therapies
por: Ghiani, Lavinia, et al.
Publicado: (2022)

Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer
por: Polten, Robert, et al.
Publicado: (2022)

Tumor Organoid and Spheroid Models for Cervical Cancer
por: Kutle, Ivana, et al.
Publicado: (2023)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Current Progress of CAR-NK Therapy in Cancer Treatment
por: Pang, Zhaojun, et al.
Publicado: (2022)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Morphological and molecular motifs of fibrosing pulmonary injury patterns
por: Jonigk, Danny, et al.
Publicado: (2019)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Incidence and survival of HNSCC patients living with HIV compared with HIV-negative HNSCC patients
por: Haase, Katharina, et al.
Publicado: (2021)

CAR T cells for treating autoimmune diseases
por: Blache, Ulrich, et al.
Publicado: (2023)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

CAR‐NK cell in cancer immunotherapy; A promising frontier
por: Marofi, Faroogh, et al.
Publicado: (2021)

CAR-NK cells for cancer immunotherapy: from bench to bedside
por: Zhang, Leisheng, et al.
Publicado: (2022)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u0c2k8722ckpk25hvj6jtra2gd